Accelerate Antibody Therapeutic Development with Expert Bioanalytical Support

Sword Bio provides bioanalytical support for a wide range of antibody-based therapeutics, including monoclonal antibodies (mAbs), multidomain proteins (bispecifics, etc.), antibody-drug conjugates (ADCs), and biosimilars.

We develop, validate, and perform pharmacokinetic (PK), anti-drug antibody (ADA), neutralizing antibody (NAb), and biomarker assays. Our team also supports assay transfer, qualification, validation, and clinical sample analysis.

Sword Bio primarily utilizes ELISA and MSD (Meso Scale Discovery) platforms to generate robust, reproducible data for pharmacokinetic, immunogenicity, and biomarker assessments.

Yes. We support antibody therapeutic programs from discovery and preclinical development through clinical studies, providing bioanalytical data that informs critical development and regulatory decisions.

Most projects can be initiated within 10–15 business days. Our streamlined onboarding process helps sponsors maintain development timelines and rapidly generate the data needed to advance their programs.

Yes. Our scientists design, optimize, qualify, and validate bioanalytical assays according to current regulatory expectations and industry best practices.

Absolutely. We provide comprehensive study documentation, validation reports, and regulatory-ready data packages designed to support IND, BLA, and other global regulatory submissions.

Sword Bio provides direct access to experienced scientists throughout the project lifecycle. The same team that develops and validates your assay leads sample analysis and reporting, ensuring continuity, scientific rigor, and efficient communication.

No. We support projects of all sizes, from a single assay qualification to large-scale clinical sample analysis programs.

Contact our team to discuss your antibody therapeutic program, study objectives, and timelines. We'll work with you to define a bioanalytical strategy tailored to your development needs.